All In MedTech

FDA Clearance Tracker · P200026-S005

Abre Venous Self-expanding Stent System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 22, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 22, 2022

Approved

Time to decision

35 days

Received Jun 17, 2022. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P200026-S005
Device name
Abre Venous Self-expanding Stent System
Applicant location
Plymouth, MN
Received
Jun 17, 2022
Decided
Jul 22, 2022
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - PAS
Original approval
P200026

Device type

Device class
Class III

Every decision under product code QAN

FDA's approval statement

As written in FDA's record.

Approval for updates to the labeling to include long-term results from the ABRE Continued Follow-Up Study.

Source documents

Other decisions for Medtronic Vascular, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.